Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Piccart

Showing results (181-190 of 186) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 186 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupF H van Wijk, M S Aapro, G Bolis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2018
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et alP Dubsky, G Curigliano, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survivalY Wang, D Drubay, S F Jonas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 19

Showing results (181-190 of 186) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 186 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupF H van Wijk, M S Aapro, G Bolis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2018
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et alP Dubsky, G Curigliano, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survivalY Wang, D Drubay, S F Jonas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 19